Medicine Recommendations

Diabetic macular oedema (NICE TA301)

NICE TA301 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271)

Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (NICE TA613)

Fluocinolone acetonide intravitreal implant for treating recurrent noninfectious uvetitis (NICE TA590)

NICE TA 590 - Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis

Prophylaxis of dental caries

Treatment of head and neck cancer patients who have had surgery, radiotherapy and/or chemotherapy

Treatment of Actinic Keratosis

Topical treatment of superficial pre-malignant skin lesions.

Treatment of small superficial basal-cell carcinomas in adults

Premature ejaculation

Depressive illness, Bulimia Nervosa, Obsessive Compulsive Disorder

MHRA Drug Safety Update  - Fluoxetine: possible small risk of congenital cardiac defects

Depressive illness

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Schizophrenia

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Treatment of schizophrenia and psychoses

Maintenance in schizophrenia and other psychoses

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Insomnia (short term use)

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist.

Asthma in adults aged 17 and over

Asthma in children aged 12 to 16

COPD

Refer to LSCMMG COPD Guidelines

Depressive illness, obsessive compulsive disorder

The colour classification was determined as part of the collaborative work between LCFT and medicines management leads. Local pathways and patient safety were taken into consideration.